Wisp, a Telesalud company for women, announced last week that it has launched a diagnostic arm, which offers test kits at home for several health conditions.
Wisp, based in New York City, is a direct consumer company that offers treatments for different sexual and reproductive health needs, including contraceptives, sexually transmitted diseases and hormonal health.
To begin with, the diagnostic arm will offer evidence of chlamydia, gonorrhea, tricyaniasis and mycoplasma genitalium. WISP members provide swabs and urine samples and send them to a laboratory accredited by CLIA/CAP with a prepaid label. Then they receive results in three or five business days. According to the test results, the company can also provide monitoring care. The evidence costs between $ 99 and $ 149.
“We launched evidence at home to close a critical gap in women’s medical care, access to timely and affordable diagnoses, complete with our wide range of treatment options,” said Monica Cepak, CEO of Wisp, in an email. “When introducing the tests at home with the incorporated monitoring care, we are simplifying the path to treatment and creation an experience of 360 degree telesalud without problems, which allows our more than 1.5 million patients with previous detection and ontement.”
Previously, Wisp had to send patients to external partners for diagnosis. However, in a recently survey, 62% of patients with WISP showed interest in sexually transmitted infection (STIs) tests. Chlamydia, gonorrhea and trichomoniasis are some of the most common STIs, particularly for women under 25 years.
To measure the success of this new offer, the company will track the percentage of patients requesting a test kit, will complete the test process and participate in WISP monitoring care, according to CEPAK. Wisp also listen to the qualitative comments of patients.
“These contributions will help us promote more impulse in our efforts to obtain awareness of these products and iterate in proactive educational messages to guarantee the highest quality of care for our patients,” he said.
He added that the company plans to expand the diagnostic arm in the future, specifically for fertility and menopause.
When launching the diagnostic arm, Wisp aims to “complete the circle of attention,” according to Cepak.
“By bringing tests at home and monitoring treatment under the same roof, we are eliminating fragmentation and delays that also or accompany medical care for women,” said Cepak. “We want it to be as easy as possible for patients to take control of their health, without sacrificing privacy, affordability or quality.”
Several other digital health companies also offer ITS tests at home, including Everlywell and Letgetchecked.
Wisp has had a year occupied so far. In March, it offers a couple of male bacterial vaginosis. And in December, he launched an association with the Nourish Nutrition Company to support patients taking LPG-1.